



SZABO SCANDIC

Part of Europa Biosite

Produktinformation



Forschungsprodukte & Biochemikalien



Zellkultur & Verbrauchsmaterial



Diagnostik & molekulare Diagnostik



Laborgeräte & Service

Weitere Information auf den folgenden Seiten!
See the following pages for more information!



Lieferung & Zahlungsart

siehe unsere [Liefer- und Versandbedingungen](#)

Zuschläge

- Mindermengenzuschlag
- Trockeneiszuschlag
- Gefahrgutzuschlag
- Expressversand

SZABO-SCANDIC HandelsgmbH

Quellenstraße 110, A-1100 Wien

T. +43(0)1 489 3961-0

F. +43(0)1 489 3961-7

mail@szabo-scandic.com

www.szabo-scandic.com

[linkedin.com/company/szaboscandic](https://www.linkedin.com/company/szaboscandic) 

Anti-human Galectin 9 [1G3] Standard Size Ab04373-10.3

This antibody was created using our proprietary Fc Silent™ engineered Fc domain containing key point mutations that abrogate binding to Fc gamma receptors.

This is a reformatted human IgG1 Fc Silent Fc Silent™ antibody, based on the original human IgG1 format, created for improved compatibility with existing reagents, assays and techniques.

Isotype and Format: Human IgG1, Fc Silent™, Kappa

Clone Number: 1G3

Alternative Name(s) of Target: Galectin-9; Gal-9; LGALS9; Ecalectin; Tumor antigen HOM-HD-21

UniProt Accession Number of Target Protein: O00182

Published Application(s): Blocking, functional assays, neutralization, WB, ELISA, IHC

Published Species Reactivity: Human, Mouse

Immunogen: The original antibody was generated by immunizing BALB/c mice with a recombinant c-terminus galectin-9 (residues 191 to 355 of the galectin-9 long isoform).

Specificity: This antibody is specific for human Gal-9 but exhibits cross-binding of murine Gal-9.

Application Notes: The binding and binding specificity of the original format of this antibody to c-terminus Gal-9 were assessed via ELISA. Epitope mapping was also done using ELISA. Furthermore, this antibody was successfully used in WB and IHC assays (Barjon et al., 2012; PMID: 22805533). An scFv-CAR version of this antibody with therapeutic potential was developed and described (US20230295564A1). This antibody was successfully used to neutralize LGALS9 in a study focused on pancreatic neoplastic lesions (Quilbe et al., 2023; PMID: 38098486). This antibody was used in a T lymphocyte proliferation assay, specifically in assessing the immunomodulatory properties of extracellular vesicles (C15SEVs) derived from nasopharyngeal carcinoma and recombinant Galectin-9S. In this assay, the antibody was used to block the impact of C15SEVs and recombinant Galectin-9 on peripheral blood mononuclear cells (Lefebvre et al., 2023; PMID: 38117000).

Antibody First Published in: Barjon et al. A novel monoclonal antibody for detection of galectin-9 in tissue sections: application to human tissues infected by oncogenic viruses. Infect Agent Cancer. 2012 Jul 17;7(1):16. PMID:22805533

Note on publication: The original publication presents the development of monoclonal antibodies targeting galectin-9 and focuses on the development and characterization of a novel monoclonal antibody, 1G3, with a particular emphasis on its application in improving the detection and understanding of galectin-9 expression in clinical samples.

Product Form

Size: 100 µg Purified antibody.

Purification: Protein A affinity purified

Supplied In: PBS with 0.02% Proclin 300.

Storage Recommendation: Store at 4°C for up to 3 months. For longer storage, aliquot and store at -20°C.

Concentration: 1 mg/ml.

Important note - This product is for research use only. It is not intended for use in therapeutic or diagnostic procedures for humans or animals.